BeOne Medicines (BEIGF) Other Operating Expenses (2017 - 2023)

BeOne Medicines (BEIGF) has 7 years of Other Operating Expenses data on file, last reported at $188000.0 in Q2 2023.

• Other Operating Expenses for Q2 2023 came in at $188000.0, down 99.74% year-over-year; the trailing twelve-month figure through Mar 2024 was $188000.0 (up 100.29% YoY), and the FY2020 annual result was $71.5 million, down 1.4% from the prior year.
• Other Operating Expenses climbed to $188000.0 in Q2 2023 per BEIGF's latest filing, from $187000.0 in the prior quarter.
• Over five years, Other Operating Expenses peaked at $76.7 million in Q3 2022 and troughed at -$213.5 million in Q4 2022.
• A 5-year average of $8.0 million and a median of $19.4 million in 2019 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2019 and 2021: Other Operating Expenses soared 229.08% in 2019, then tumbled 649.82% in 2021.
• A 5-year view of Other Operating Expenses shows it stood at $18.3 million in 2019, then grew by 16.11% to $21.3 million in 2020, then plunged by 649.82% to -$116.9 million in 2021, then tumbled by 82.61% to -$213.5 million in 2022, then jumped by 100.09% to $188000.0 in 2023.
• Business Quant data shows BEIGF's Other Operating Expenses at $188000.0 in Q2 2023, $187000.0 in Q1 2023, and -$213.5 million in Q4 2022.